Delayed-Action Preparations
"Delayed-Action Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
| Descriptor ID |
D003692
|
| MeSH Number(s) |
D26.255.210 E02.319.300.253
|
| Concept/Terms |
Controlled-Release Preparations- Controlled-Release Preparations
- Controlled Release Preparations
- Controlled-Release Preparation
- Controlled-Release Formulations
- Controlled Release Formulations
- Controlled-Release Formulation
Sustained-Release Preparations- Sustained-Release Preparations
- Sustained-Release Preparation
- Extended Release Preparations
- Extended Release Preparation
- Slow Release Formulation
- Sustained Release Formulations
- Sustained Release Formulation
- Extended Release Formulations
- Extended Release Formulation
|
Below are MeSH descriptors whose meaning is more general than "Delayed-Action Preparations".
Below are MeSH descriptors whose meaning is more specific than "Delayed-Action Preparations".
This graph shows the total number of publications written about "Delayed-Action Preparations" by people in this website by year, and whether "Delayed-Action Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Delayed-Action Preparations" by people in Profiles.
-
Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone. Drug Saf. 2018 10; 41(10):979-980.
-
Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. Am J Addict. 2016 12; 25(8):666-672.
-
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 2015 Sep 01; 154:38-45.
-
Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend. 2015 Feb 01; 147:122-9.
-
A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Treat. 2014 May-Jun; 46(5):546-52.
-
Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Drug Alcohol Depend. 2013 Nov 01; 133(1):80-5.
-
An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder. Am J Drug Alcohol Abuse. 2011 Sep; 37(5):392-9.
-
Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010 Dec; 71(12):1680-8.
-
Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ. 2010 Feb; 11(1):35-44.
-
Canary in a coal mine? Interest in bupropion SR use among smokers in the COMPASS trial. Nicotine Tob Res. 2008 Dec; 10(12):1815-6.